ISSN: 2456-8503

International Journal for Development of Science and Technology (IJDST)

Nanoparticle Based Drug Delivery System-Designing Polymeric Nanoparticle for Controlled and Targeted Drug Delivery

REVIEW

Babitha[1], Kamaleshwari[2], Padma Preetha[3], Gayathri[4], Sankar[5]*

Abstract

The development of nanoparticle-based drug delivery systems represents a major step forward in pharmaceutical science, with the goal of enhancing treatment effectiveness while ensuring patient safety. Among these systems, polymeric nanoparticles-especially those made from biodegradable materials-have gained considerable interest due to their biocompatibility and versatile structural properties. Through careful formulation approaches, including surface modification, appropriate polymer selection, and optimization of physicochemical properties, these carriers can achieve sustained and controlled drug release. Such controlled release helps maintain stable drug levels in the bloodstream, reduces dosing frequency, and minimizes adverse effects. Furthermore, incorporating targeting strategies allows for more precise drug delivery by promoting accumulation at specific sites of action. In addition, advanced stimuli-responsive systems introduce an extra level of regulation, enabling drug release in response to specific biological triggers like pH changes, temperature variations, or enzymatic activity. This review highlights key design principles, explores mechanisms underlying controlled and targeted delivery, and discusses the growing importance of smart polymeric systems in the evolving field of nanomedicine.

Keywords: *Polymeric Nanoparticles, Targeted Drug Delivery, Controlled Release, Nanomedicine, Biodegradable Polymers Stimuli-responsive Systems.*

1. Introduction

Nanoparticle-based drug delivery systems have emerged as sophisticated therapeutic platforms designed to address the limitations of conventional dosage forms, including dose-dependent toxicity, non-specific distribution, rapid clearance, and poor solubility. Owing to their ability to provide precise control over drug release, improve bioavailability, and enhance therapeutic outcomes, nanoparticulate carriers have become a key focus in modern drug delivery research [1].

Among various nanocarriers, Polymeric Nanoparticles (PNPs) are particularly prominent due to their biocompatibility, biodegradability, and adaptability in design. Typically ranging from 10 to 500 nm in size, these systems can encapsulate or conjugate drugs, protecting them from degradation while enabling controlled release profiles [2]. Both natural and synthetic polymers can be employed, allowing customization of nanoparticle properties to meet specific therapeutic needs [3]. The biological performance of polymeric nanoparticles is largely influenced by their physicochemical properties, including particle size, surface charge, polymer composition, and surface modifications. Careful optimization of these parameters determines their circulation time, cellular internalization, bio distribution, and interaction with physiological barriers, ultimately impacting therapeutic efficacy [4]. Controlled drug delivery through polymeric nanoparticles can occur via diffusion, polymer

[1] *I - M.Pharm, Department of Pharmaceutics, KMCH College of Pharmacy, Tamil Nadu, India.*

[2*] *Assistant Professor, Department of Pharmaceutics, KMCH College of Pharmacy, Tamil Nadu, India.*

[3] *Associate Professor, Department of Pharmaceutics, KMCH College of Pharmacy, Tamil Nadu, India.*

[4,5] *Professor, Department of Pharmaceutics, KMCH College of Pharmacy, Tamil Nadu, India.*

[*] *Corresponding Author: kamaleshwari.b@kmchcop.ac.in*

Doi: https://doi.org/10.26524/ijdst.1.4

degradation, or swelling mechanisms. These systems help maintain drug concentrations within the therapeutic range for extended durations, thereby reducing dosing frequency and improving patient adherence [5]. Beyond controlled release, polymeric nanoparticles also facilitate targeted drug delivery. Passive targeting utilizes the Enhanced Permeability and Retention (EPR) effect observed in diseased tissues, while active targeting involves surface modification with ligands such as antibodies, peptides, or small molecules to achieve receptor-specific delivery [6]. Although polymeric nanoparticle systems have demonstrated promising results in preclinical studies, their clinical translation remains limited. Challenges such as formulation instability, scalability issues, reproducibility concerns, and regulatory hurdles need to be addressed to enable successful clinical application [7]. This review focuses on the development of polymeric nanoparticles for controlled and targeted drug delivery, highlighting key aspects such as polymer selection, formulation techniques, release mechanisms, targeting approaches, biological applications, and future research directions.

2. Nanoparticle-Based Drug Delivery Systems

Nanoparticle-based Drug Delivery Systems (NDDS) represent an advanced approach aimed at enhancing drug stability, bioavailability, and targeted distribution. These systems utilize carriers in the nanoscale range, which improves their interaction with biological membranes and facilitates efficient delivery to specific sites of action. Due to their small size and customizable surface properties, nanoparticles can address many limitations associated with traditional drug delivery, such as poor solubility, rapid degradation, and non-specific distribution. A key advantage of these systems is their ability to provide controlled and sustained drug release, ensuring that therapeutic concentrations are maintained over extended periods. This not only reduces the need for frequent dosing and difficulties in large-scale production. Current research as but also helps in minimizing systemic side effects. Drug release profiles can be adjusted by altering factors such as carrier composition, particle size, and surface characteristics. Nanoparticles support both passive and active targeting mechanisms. Passive targeting relies on the Enhanced Permeability and Retention (EPR) effect, particularly in tumor tissues where leaky vasculature allows nanoparticles to accumulate selectively. In contrast, active targeting involves modifying the nanoparticle surface with ligands such as antibodies, peptides, or sugars that bind to specific receptors overexpressed on diseased cells, thereby improving cellular uptake and therapeutic effectiveness. A wide range of materials is used in nanoparticle formulation, including biodegradable polymers, lipids, and inorganic substances. Polymeric nanoparticles are extensively studied due to their biocompatibility, biodegradability, and ability to carry both hydrophilic and hydrophobic drugs. Lipid-based nanoparticles, on the other hand, are valued for their lower toxicity and improved drug stability [8-10]. Despite their potential, nanoparticle-based drug delivery systems face several challenges, including rapid clearance by the reticuloendothelial system, possible toxicity concerns, and difficulties in large-scale production. Current research efforts are focused on improving nanoparticle design and surface modification techniques to enhance their safety, stability, and suitability for clinical use [11].

3. Fundamentals of Polymeric Nanoparticles

3.1. Definition and Classification

Polymeric nanoparticles are colloidal drug carriers formed from either natural or synthetic polymers, generally ranging in size from 10 to 1000 nm. They are developed to enhance therapeutic outcomes by improving drug solubility, stability, bioavailability, and targeted delivery to specific sites [12]. Owing to their nanoscale dimensions and tunable characteristics, these systems can influence drug release patterns as well as interactions at cellular and molecular levels [13]. Based on their structural arrangement, polymeric

nanoparticles are mainly categorized into two types nanospheres and nanocapsules.

3.1.1. Nanospheres

Nanospheres are matrix-type polymeric nanoparticles in which the drug is uniformly dispersed or molecularly dissolved within the polymer network. In some cases, the drug may also be adsorbed onto the particle surface. Drug release from nanospheres generally occurs through mechanisms such as diffusion, polymer swelling, or gradual polymer degradation, depending on the nature of the polymer used [14]. These systems are especially suitable for sustained and controlled drug delivery, and are commonly prepared using biodegradable polymers like Poly Lactic Acid (PLA) and Poly Lactic-co-Glycolic Acid (PLGA) (Figure 1) [15].

3.1.2. Nanocapsules

Nanocapsules are vesicular systems consisting of a polymeric shell that surrounds a liquid or solid core containing the drug. In this structure, the drug is predominantly localized within the core, providing enhanced protection for sensitive molecules such as peptides and proteins against degradation. Drug release from nanocapsules mainly occurs through diffusion across the polymeric membrane or by rupture of the shell [16]. These systems are particularly beneficial for targeted drug delivery and for minimizing the initial burst release of the drug (Figure 2) [17].



Figure 1: Controlled Drug Release



Figure 2: Targeted Drug Delivery

3.2. Physicochemical Properties Influencing Drug Delivery

The performance of polymeric nanoparticles as drug carriers is strongly governed by their physicochemical properties, as these factors influence their behavior in the body, cellular uptake, and overall therapeutic outcomes.

3.3. Particle Size and Size Distribution

Particle size plays a crucial role in determining circulation time, bio distribution, cellular internalization, and drug release characteristics. Nanoparticles within the range of 50-200 nm are generally preferred for systemic delivery, as they can evade rapid renal elimination and take advantage of the Enhanced Permeability and Retention (EPR) effect in tumor tissues [18]. In addition, a narrow size distribution-indicated by a low Polydispersity Index (PDI) is essential to ensure formulation uniformity, reproducibility, and consistent pharmacokinetic behavior.

3.4. Surface Charge (Zeta Potential)

Zeta potential is an important indicator of colloidal stability and reflects the surface charge present on nanoparticles. Particles with high positive or negative zeta potential values tend to repel each other, which helps prevent aggregation during storage and in circulation [19]. Surface charge also plays a significant role in interactions with biological systems, including plasma proteins and cell membranes. Positively charged nanoparticles generally exhibit enhanced cellular uptake due to electrostatic attraction with negatively charged cell surfaces, whereas neutral or slightly negatively charged particles are associated with prolonged circulation times [20].

3.5. Morphology and Porosity

The shape and surface architecture of polymeric nanoparticles play a key role in drug loading, release behavior, and cellular uptake. Spherical particles are commonly preferred due to their uniform distribution and consistent flow properties. The porosity of the polymer matrix

also influences drug release patterns compact structures tend to provide sustained release, while highly porous systems may lead to faster drug diffusion and release [21]. These morphological features are primarily determined by the formulation method and the type of polymer used [22].

3.6. Drug Loading and Encapsulation Efficiency

Encapsulation efficiency refers to the proportion of drug successfully incorporated into the nanoparticles during formulation, while drug loading indicates the amount of drug present relative to the total weight of the nanoparticle system. Achieving high values for both is desirable, as it reduces the amount of carrier required and helps minimize potential carrier-related toxicity while maintaining therapeutic effectiveness [23]. These parameters are influenced by several factors, including the preparation technique, drug solubility, polymer molecular weight, and the compatibility between the drug and the polymer [24].

4. Polymers Used in Nanoparticle Design

Polymers play a central role in nanoparticle-based drug delivery systems, as they determine key attributes such as stability, drug loading capacity, release behavior, and overall biological performance. Based on their source, the polymers utilized in nanoparticle formulation are generally classified into two main groups: natural polymers and synthetic polymers.

4.1. Natural Polymers

Natural polymers are widely utilized in nanoparticle formulation due to their inherent biocompatibility, biodegradability, and minimal toxicity, making them highly suitable for biomedical applications.

4.1.1. Chitosan

Chitosan is a naturally derived cationic polymer obtained through the deacetylation of chitin. Its positive charge enables strong interactions with negatively charged drugs and biological membranes, thereby enhancing mucoadhesion and cellular uptake. Chitosan-based nanoparticles are extensively studied for oral, nasal, ocular, and gene delivery applications. However, their limited solubility at physiological pH remains a notable limitation [25].

4.1.2. Alginate

Alginate is an anionic polysaccharide composed of mannuronic and guluronic acid units, typically extracted from brown algae. It forms nanoparticles mainly through ionic crosslinking with divalent cations, allowing mild and gentle preparation conditions. Alginate nanoparticles are commonly used for the controlled and sustained delivery of proteins and peptides due to their ability to encapsulate sensitive molecules without degradation [26].

4.1.3. Gelatin

Gelatin is a protein-based natural polymer derived from the hydrolysis of collagen. It is highly biocompatible and biodegradable, and can be easily cross-linked or modified to enhance nanoparticle stability. Gelatin nanoparticles are widely applied in controlled drug release and targeted delivery systems, particularly in cancer therapy [27].

4.1.4. Dextran

Dextran is a hydrophilic polysaccharide produced through microbial fermentation. It exhibits low immunogenicity and high water solubility, which supports extended circulation in the body. Dextran-based nanoparticles are often used for delivering macromolecules and for passive targeting, especially after chemical modification to improve drug loading capacity [28].

4.2. Synthetic Polymers

Synthetic polymers offer significant advantages in nanoparticle-based drug delivery, including reproducibility, well-defined molecular weights, and the ability to tailor degradation rates. These properties enable precise control over the design and performance of delivery systems.

4.2.1. Poly Lactic-co-Glycolic Acid (PLGA)

PLGA is a widely used biodegradable copolymer that has

received regulatory approval for pharmaceutical applications. It degrades into lactic acid and glycolic acid, both of which are naturally metabolized in the body. By altering the ratio of lactic to glycolic units, the drug release profile of PLGA nanoparticles can be finely tuned to achieve sustained and controlled delivery.

4.2.2. Poly Lactic Acid (PLA)

PLA is biodegradable aliphatic polyester derived from lactic acid. It is known for its good mechanical strength and relatively slow degradation, making it suitable for long-term drug delivery applications. However, its hydrophobic nature may hinder the encapsulation of hydrophilic drugs, which can be improved through polymer blending or surface modification techniques [29].

4.2.3. Polycaprolactone (PCL)

PCL is a semi crystalline polymer with a slow degradation rate and high permeability to drugs. These characteristics make it particularly useful for extended drug release systems. It is often combined with other polymers to better control its degradation behavior and optimize drug release patterns [30].

4.2.4. Polyethyleneglycol (PEG)

PEG is a hydrophilic polymer primarily used to modify the surface of nanoparticles, a process known as PEG-ylation. This modification enhances stability, reduces protein adsorption (Opsonization), and extends circulation time in the bloodstream. PEG-coated nanoparticles are commonly employed to improve pharmacokinetics and facilitate passive targeting [31].

5. Methods of Preparation Polymeric Nanoparticle

5.1. Emulsion Solvent Evaporation Method

The emulsion solvent evaporation technique is a commonly employed method for preparing polymeric nanoparticles. In this approach, the drug and polymer such as (PLA or PLGA) are initially dissolved in a volatile, water-insoluble organic solvent like dichloromethane or chloroform. This organic phase is then dispersed into an aqueous phase containing a stabilizer or surfactant to form an Oil-in-Water (O/W) emulsion. High-energy processes, including homogenization or ultra-sonication, are typically applied to reduce droplet size and improve emulsion stability. Following emulsion formation, the organic solvent is removed through continuous stirring or reduced-pressure evaporation, leading to polymer solidification and nanoparticle formation. Key formulation parameters-such as stirring speed, polymer concentration, and the type of surfactant used-can be adjusted to control particle size, drug loading, and surface properties (Figure 3) [32].

Figure 3: Emulsion Solvent Evaporation Method

5. 2. Nano Precipitation Method

Nano precipitation, also referred to as the solvent displacement technique, is a simple and rapid approach for preparing polymeric nanoparticles, especially suitable for hydrophobic polymers. In this method, the polymer is first dissolved in a water-miscible organic solvent such as acetone or acetonitrile. The resulting organic solution is then added gradually-often drop wise into an aqueous phase under constant stirring. As the organic solvent mixes with water, it diffuses rapidly into the aqueous phase, leading to super saturation of the polymer. This triggers immediate precipitation of the polymer in the form of nanoparticles. Although surfactants can be added to enhance particle stability, their use is optional. This technique generally produces nanoparticles with a narrow size distribution and can be adapted to form either nanospheres or nanocapsules depending on the formulation conditions (Figure 4).

Figure 4: Nano Precipitation Method

5.3. Salting-Out Method

The salting-out technique is used to prepare polymeric nanoparticles by taking advantage of the reduced miscibility of an organic solvent in water in the presence of high concentrations of salting-out agents. In this process, the polymer and drug are first dissolved in a water-miscible organic solvent such as acetone or tetrahydrofuran. This solution is then emulsified into an aqueous phase containing a stabilizer along with a salting-out agent (magnesium chloride) or a non-electrolyte such as sucrose. The high concentration of these agents prevents the immediate mixing of the organic solvent with water, allowing the formation of a stable emulsion. When a large volume of water is subsequently added, the organic solvent diffuses into the aqueous phase, leading to polymer precipitation and nanoparticle formation. This method minimizes the need for high-energy emulsification and often reduces the use of more hazardous organic solvents (Figure 5) [33].



Figure 5: Salting-Out Method

5.4. Spray Drying Method

Spray drying is a technique used to convert a liquid polymer solution or suspension into dry polymeric nanoparticles through rapid solvent evaporation. In this process, the polymer and drug are either dissolved or dispersed in a suitable liquid, which is then atomized into fine droplets using a spray nozzle or atomizer. These droplets are introduced into a chamber containing hot drying gas, typically heated air. Upon contact with the hot gas, the solvent evaporates almost instantly, resulting in the formation of solid polymeric particles that are collected using devices such as cyclone separators or filters. While spray drying is an efficient method for producing dry nanoparticles, careful control of processing conditions is necessary when working with heat-sensitive drugs. Advances in Nano-spray drying technologies have helped minimize thermal degradation during the process (Figure 6) [34].

Figure 6: Spray Drying Method

6. Drug Loading and Encapsulation Mechanisms

6.1. Physical Encapsulation

Physical encapsulation involves entrapping drug molecules within the polymer matrix or core during the formation of polymeric nanoparticles. The drug is retained through non-covalent interactions such as hydrogen bonding and hydrophobic forces. This method is widely used due to its simplicity and high encapsulation efficiency, particularly for hydrophobic drugs.

6.2. Chemical Conjugation

Chemical conjugation refers to the covalent linkage of drug molecules to polymer chains using biodegradable bonds such as ester or amide linkages. Drug release occurs only after these bonds are cleaved, allowing for controlled and site-specific delivery. This strategy improves drug stability and reduces the risk of premature drug leakage [35].

6.3. Surface Adsorption

Surface adsorption is a post-loading approach in which drugs are attached to the surface of already formed polymeric nanoparticles through electrostatic or hydrophobic interactions. Although this method is straightforward and suitable for hydrophilic or charged drugs, it generally offers lower encapsulation efficiency and may lead to faster drug release [36].

7. Controlled Drug Delivery Mechanisms

7.1. Diffusion-Controlled Release

In diffusion-controlled systems, drug release is driven by a concentration gradient between the formulation and the surrounding biological environment. The drug migrates either through pore within a polymer matrix (matrix-type systems) or across a surrounding polymer membrane (reservoir-type systems). Throughout this process, the polymer structure remains intact, and the release rate is largely influenced by the drug's diffusion coefficient and the characteristics of the polymer [37].

7.2. Degradation-Controlled Release

Degradation-controlled release occurs when the polymer undergoes breakdown through hydrolytic or enzymatic processes. As the polymer chains degrade, the encapsulated drug is progressively released. The rate of drug release is closely linked to the degradation kinetics of the polymer, making biodegradable materials such as PLGA particularly suitable for prolonged and controlled delivery applications [38].

7.3. Swelling-Controlled Release

Swelling-controlled systems rely on hydrophilic polymers that absorb surrounding biological fluids and expand. This swelling increases the pore size of the polymer network, enabling the drug to diffuse outward. In such systems, drug release is governed not only by diffusion but also by the rate of polymer swelling and relaxation of polymer chains [39].

8. Stimuli-Responsive Drug Delivery System

Stimuli-responsive drug delivery systems are smart carriers that release drugs in reaction to certain biological signals, improving targeted treatment and reducing side effects. To regulate medication release, these systems take advantage of variations between healthy and pathological settings.

8.1. pH-Responsive Systems

Principle: These carriers alter their physicochemical properties, such as solubility or degree of swelling, in response to variations in pH.

Mechanism: While normal tissues and blood maintain a pH of around 7.4, tumor and inflamed tissues tend to be more acidic (approximately 6.5), allowing selective drug release in these environments.

Application: Widely used in targeted cancer therapy and for site-specific drug delivery within different regions of the gastrointestinal tract.

8.2. Temperature-Responsive Systems

Principle: These systems respond to temperature changes by undergoing phase transitions that influence drug retention and release.

Mechanism: Thermo-sensitive polymers can shift between hydrophilic and hydrophobic states at specific temperatures. Slightly elevated temperatures, such as those found in tumor tissues, can trigger this transition and promote drug release.

Application: Applied in controlled drug delivery for cancer treatment and in therapies involving localized hyperthermia.

8.3. Enzyme-Responsive Systems

Principle: These carriers are engineered with enzyme-sensitive linkages or structures that break down in the presence of specific enzymes.

Mechanism: Certain pathological conditions, including tumors and inflamed tissues, exhibit increased levels of enzymes such as proteases, phospholipases, and glycosidase. These enzymes facilitate degradation of the carrier, leading to drug release.

Application: Enables precise drug delivery at targeted sites, particularly in inflammatory and cancer-related conditions [40].

9. Targeted Drug Delivery Strategies

Polymeric nanoparticles are extensively utilized in targeted drug delivery due to their biocompatibility, biodegradability, and ease of functional modification. By adjusting parameters such as particle size, composition, and surface properties, these carriers can be engineered to deliver drugs more selectively to diseased tissues. Targeting with polymeric nanoparticles is generally achieved through two main approaches passive and active targeting.

9.1. Passive Targeting

Passive targeting exploits the inherent physiological differences between healthy and diseased tissues. In conditions such as cancer and inflammation, blood vessels are often more permeable and lymphatic drainage is impaired. As a result, nanoparticles within the nanoscale range tend to accumulate preferentially at these sites through the Enhanced Permeability and Retention (EPR) effect. The use of polymers like PLGA or PEG-coated nanoparticles can prolong circulation time, thereby increasing the likelihood of drug accumulation in the affected area without the need for specific targeting ligands.

9.2. Active Targeting

Active targeting involves the attachment of specific ligands-such as antibodies, peptides, sugars, or folic acid-to the surface of polymeric nanoparticles. These ligands bind to receptors that are overexpressed on target cells, enabling receptor-mediated uptake. This approach enhances cellular internalization of the drug, improves therapeutic effectiveness, and minimizes damage to healthy tissues. Active targeting is especially beneficial when high specificity is required or when passive targeting alone does not provide sufficient selectivity [41].

10. Biomedical Applications

10.1. Cancer Therapy

Targeted drug delivery has become increasingly important in oncology to enhance treatment efficacy while minimizing systemic toxicity. Traditional chemotherapeutic agents often affect healthy tissues, leading to severe side effects and limited therapeutic windows. Advanced delivery systems such as dendrimers, micelles, and polymeric nanoparticles enable the encapsulation of anticancer drugs and promote their preferential accumulation at tumor sites by exploiting tumor-specific features like the Enhanced Permeability and Retention (EPR) effect. These nanocarriers also facilitate combination approaches, including chemo-immunotherapy, and support imaging-guided treatments, thereby improving therapeutic outcomes and reducing off-target effects.

10.2. Gene Delivery

Gene delivery involves introducing genetic material-such as DNA, RNA, or gene-editing components-into target cells to regulate or correct abnormal gene expression. While viral vectors offer high transfection efficiency, their use is limited by concerns such as immunogenicity and inspectional mutagenesis. Non-viral systems, including lipid-based nanoparticles and biodegradable polymers, provide safer and more versatile alternatives. These carriers protect genetic material from degradation, enhance cellular uptake, and allow controlled release, making them valuable in applications such as genetic disorders, cancer immunotherapy, and regenerative medicine.

10.3. Vaccine Delivery

Successful vaccination depends on efficient delivery of antigens to immune cells, particularly antigen-presenting cells. Advanced delivery platforms, including nano and micro particles, improve the stability and presentation of vaccine components. By shielding sensitive antigens and enabling sustained release, these systems enhance immune responses and may reduce the number of required doses. Additionally, the incorporation of adjuvants or targeting ligands can direct antigens to specific immune cells, increasing vaccine effectiveness against infectious diseases and cancer while minimizing adverse reactions.

10.4. Infectious Disease Treatment

Targeted delivery strategies are increasingly used to improve the effectiveness of antimicrobial therapies and address drug resistance. Encapsulation of antibiotics, antifungals, or antiviral agents within nanocarriers enhances drug solubility, protects against premature degradation, and enables localized release at infection sites. These systems also allow the co-delivery of multiple drugs, which is beneficial in treating multidrug-resistant infections while reducing systemic toxicity. Surface modification of carriers can further improve interaction with pathogens, enhancing therapeutic efficiency without disturbing normal microbial flora.

10.5. Brain Drug Delivery

The treatment of neurological disorders is often hindered by the Blood-Brain Barrier (BBB), which restricts the entry of many therapeutic agents into the central nervous system. Nano carrier-based approaches aim to overcome this limitation by facilitating transport across or around the BBB. Strategies include surface modification to utilize receptor-mediated transport pathways or transiently modulate tight junctions. Lipid-based nanoparticles, polymeric carriers, and peptide-functionalized systems have shown promising results in delivering drugs for conditions such as Parkinson's disease, Alzheimer's disease, and brain tumors, improving drug penetration while reducing peripheral side effects [42].

11. Toxicity and Safety Considerations

11.1. Cytotoxicity

Polymeric nanoparticles can exhibit cytotoxic effects due to factors such as oxidative stress, disruption of cell membranes, or mitochondrial dysfunction. The extent of toxicity is influenced by parameters like particle size, surface charge, type of polymer, and the presence of residual solvents. Biodegradable polymers, particularly PLGA, are generally associated with lower toxicity and good biocompatibility.

11.2. Immunogenicity

Nanoparticles may activate the immune system through interactions with plasma proteins and immune cells, potentially leading to inflammatory responses or hypersensitivity. Surface characteristics, including charge and hydrophobicity, significantly affect these interactions. Modifications such as PEG-ylation are commonly employed to reduce immune recognition and improve compatibility.

11.3. Long-Term Accumulation

Non-biodegradable or slowly degrading nanoparticles can accumulate in organs such as the liver and spleen, which may result in long-term toxicity. To minimize this risk, biodegradable polymers are preferred, as they break down into harmless byproducts that can be safely eliminated from the body [43].

12. Challenges in Clinical Translation

12.1. Challenges in Large-Scale Manufacturing

Scaling up nanoparticle-based systems from laboratory settings to industrial production is often difficult due to the complexity of formulations. Maintaining consistency at high production volumes can lead to problems such as batch variability, reduced yield, and reliance on specialized equipment and technical expertise, which ultimately hinders commercial implementation.

12.2. Storage Stability Issues

Many advanced therapeutic platforms, particularly nanosystems and biologics, are highly sensitive to environmental factors. Ensuring their physical and chemical stability during storage and transportation is challenging, and inadequate conditions may compromise their potency and therapeutic performance.

12.3. Regulatory Barriers

Existing regulatory frameworks, primarily designed for conventional drugs, may not fully accommodate the unique characteristics of novel nanomedicines. Ambiguities in classification, variations in international guidelines, and strict requirements for demonstrating safety and efficacy can delay approval and complicate global adoption.

12.4. High Production Costs

The development of advanced therapeutic systems involves costly raw materials, sophisticated manufacturing processes, and rigorous quality control measures. These factors significantly increase overall production expenses, potentially limiting accessibility, particularly in resource-constrained settings [44].

13. Future Perspectives in Nanomedicine

The future of nanomedicine is expected to focus on multifunctional nanoparticle systems that integrate drug delivery, targeting capabilities, and diagnostic or stimuli-responsive features within a single platform. Such systems have the potential to enhance therapeutic precision and improve disease management. Artificial Intelligence (AI) is emerging as a valuable tool in nanoparticle design, enabling prediction of optimal formulations, reducing experimental workload, and improving reproducibility and clinical translation. Additionally, personalized nanomedicine aims to customize treatments based on individual genetic and biological profiles, thereby increasing efficacy and minimizing adverse effects. To facilitate these advancements, there is a need for more robust and harmonized regulatory frameworks that emphasizes standardized characterization, safety evaluation, and assessment methods, particularly for complex and AI-driven nano medicine systems, ensuring their safe and efficient transition into clinical use [45].

14. Conclusion

Polymeric nanoparticle-based drug delivery systems represent a versatile and promising approach for achieving controlled and targeted therapeutic outcomes. Through appropriate selection of polymers and optimization of fabrication techniques, these systems can regulate drug release, enhance accumulation at specific sites, and improve bioavailability while minimizing systemic side effects. Advances in surface engineering, stimuli-responsive designs, and targeting strategies have further broadened their applications, including cancer therapy, treatment of infectious and neurological disorders, as well as gene and vaccine delivery. Despite these advantages, their transition into clinical practice remains limited due to challenges such as high production costs, stability concerns, safety issues, regulatory complexities, and difficulties in large-scale manufacturing. To bridge the gap between research and real-world application, future efforts should focus on developing scalable manufacturing processes, conducting comprehensive safety evaluations, and establishing harmonized regulatory frameworks. With these challenges effectively addressed, polymeric nanoparticles have the potential to play a transformative role in modern drug delivery and personalized medicine.

Conflict of Interest Statement: The authors declare that they have no competing interests.

Funding Information: None to be declared.

Date Availability Statement: The authors confirm that no primary data were generated for this review article. All information discussed is derived from published studies, which are appropriately cited within the manuscript.

Ethical Approval Statement: None to be stated.

Acknowledgement: The authors would like to express their sincere gratitude to the Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore, India, for providing academic support and necessary facilities for the preparation of this review article.

References

1. Ventola CL, The Nano Medicine Revolution: Part 1: Emerging Concepts, PT. 2012, 37(9):512-525
2. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MP, Acosta-Torres LS, et al., Nano Based Drug Delivery Systems: Recent Developments and Future Prospects, Journal of Nano Biotechnology. 2018, 16(1): 71
3. Idrees H, Zaidi SZJ, Sabir A, Khan RU, Zhang X, Hassan SU, A Review of Biodegradable Natural Polymer-Based Nanoparticles for Drug Delivery Applications, Nanomaterial's Basel. 2020, 10(10):1970
4. Blanco E, Shen H, Ferrari M, Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery, Nat. Biotechnology. 2015, 33(9):941-951
5. Pelaz B, Alexiou C, Alvarez-Puebla RA, Alves F, Andrews AM, Ashraf S, et al., Diverse Applications of Nano Medicine, Nat. Communication. 2017, 8:15136
6. Torchilin VP, Multifunctional, Stimuli-Sensitive Nano Particulate Systems for Drug Delivery, Nat. Rev. Drug Discov. 2014, 13(11):813-827
7. Lombardo D, Kiselev MA, Caccamo MT, Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nano Carrier Platforms in Biotechnology and Nanomedicine, Journal of Nanomaterial's. 2019, (12):1-26
8. Ghosh V, Biswas S, Nanoparticle-Based Drug Delivery Systems for Cancer Therapy, Smart Materials in Medicine. 2020, 1:10-19
9. Mashreghi M, Ramezani M, Kouhi M, Akbarzadeh A, An Overview of Nanoparticles in Drug Delivery: Properties and Applications, South African Journal of Chemical Engineering. 2023, 46:233-270
10. Jain S, Goyal AK, Khatri K, Gupta PN, Vyas SP, Nanotechnology-Based Drug Delivery Systems, J. Occup. Med. Toxicol. 2007, 2-16
11. Danaei M, Dehghankhold M, Ataei S, Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nano Carrier Systems, Pharmaceutics. 2018, 10(2):57
12. Kumari A, Yadav SK, Yadav SC, Biodegradable Polymeric Nanoparticles Based Drug Delivery Systems, Colloids Surf B Bio Interfaces. 2010, 75(1):1-18
13. Mora-Huertas CE, Fessi H, Elaissari A, Polymer-Based Nano Capsules for Drug Delivery, Int. J. Pharm. 2010, 385(1-2):113-142
14. Hans ML, Lowman AM, Biodegradable Nanoparticles for Drug Delivery and Targeting, Curr. Open Solid State Mater. Sci. 2002, 6(4):319-327
15. Makadia HK, Siegel SJ, Poly Lactic-co-Glycolic Acid as Biodegradable Controlled Drug Delivery Carrier, Polymers Basel. 2011, 3(3):1377-1397
16. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S, Nanocapsule Formation by Interfacial Polymer Deposition Following Solvent Displacement Int. J. Pharm. 1989, 55(1):R1-R4
17. Barratt G, Colloidal Drug Carriers: Achievements and Perspectives, Cell. Mo. Life Sci. 2003, 60(1):21-37
18. Petros RA, Desimone JM, Strategies in the Design of Nanoparticles for Therapeutic Applications, Nat. Rev. Drug Discov. 2010, 9(8):615-627
19. Honary S, Zahir F, Effect of Zeta Potential on the Properties of Nano-drug Delivery Systems, A Review Part 1, Trop. J. Pharm. Res. 2013,12(2):255-264
20. Albanese A, Tang PS, Chan WCW, The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems, Annu. Rev. Biomed. Eng. 2012, 14:1-16
21. Panyam J, Labhasetwar V, Biodegradable Nanoparticles for Drug and Gene Delivery to Cells and Tissue, Adv. Drug Deliv. Rev. 2003, 55(3):329-347

22. Freiberg S, Zhu XX, Polymer Microspheres for Controlled Drug Release, Int. J. Pharm. 2004, 282(1-2):1-18
23. Bilati U, Allemann E, Doelker E, Strategic Approaches for Overcoming Peptide and Protein Instability Within Biodegradable Nano and Micro Particles, Eur. J. Pharm. Bio Pharm. 2005, 59(3):375-388
24. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE, Biodegradable Polymeric Nanoparticles as Drug Delivery Devices, J. Control Release. 2001, 70(1-2):1-20
25. Rinaudo M, Chitin and Chitosan: Properties and Applications, Prog. Polym. Sci. 2006, 31(7):603-32
26. Lee KY, Mooney DJ. Alginate: Properties and Biomedical Applications. Prog. Polym. Sci. 2012, 37(1):106-26
27. Young S, Wong M, Tabata Y, Mikos AG, Gelatin as a Delivery Vehicle for the Controlled Release of Bioactive Molecules, J. Control Release. 2005, 109(1-3):256-74
28. Mehvar R, Dextrans for Targeted and Sustained Delivery of Therapeutic Agents, J. Control Release. 2000, 69(1):1-25
29. Middleton JC, Tipton AJ, Synthetic Biodegradable Polymers as Orthopaedic Devices, Biomaterials. 2000, 21(23):2335-46
30. Woodruff MA, Hutmacher DW, The Return of a Forgotten Polymer Polycaprolactone, Prog. Polym. Sci. 2010, 35(10):1217-56
31. Owens DE, Peppas NA, Opsonization, Bio Distribution, and Pharmacokinetics of Polymeric Nanoparticles, Int. J. Pharm. 2006, 307(1):93-102
32. Jafarinejad S, Preparation of Polymeric Nanoparticles: A Review, J. Drug Deliv. Sci. Technol. 2020, 60:101986
33. Quintanar Guerrero D, Allemann E, Fessi H, Doelker E, Preparation Techniques and Mechanisms of Formation of Biodegradable Nanoparticles from Preformed Polymers. Drug Dev. Ind. Pharm. 1998, 24(12):1113-1128
34. Sosnik A, Seremeta KP, Advantages and Challenges of the Spray-Drying Technology for the Production of Drug-Loaded Polymeric Carriers, Adv. Colloid Interface Sci. 2015, 223:40-54
35. Rwei AY, Wang W, Kohane DS, Photo Responsive Nanoparticles for Drug Delivery, Nano Today. 2015, 10(4):451-467
36. Crucho CIC, Barros MT, Polymeric Nanoparticles: A Study on the Preparation Variables and Characterization Methods, Mater Sci. Eng. C. 2017, 80:771-784
37. Siepmann J, Siepmann F, Modeling of Diffusion Controlled Drug Delivery, Int. J. Pharm. 2008, 364(2): 328-343
38. Kamaly N, Yameen B, Wu J, Farokhzad OC, Degradable Controlled-Release Polymers and Polymeric Nanoparticles, Chem. Rev. 2016, 116(4):2602-2663
39. Peppas NA, Sahlin JJ, A Simple Equation for the Description of Solute Release, Int. J. Pharm. 1989, 57(2):169-172
40. Zhang Y, Wu BM, Current Advances in Stimuli Responsive Hydrogels as Smart Drug Delivery Carriers, Gels. 2023, 9(10):838
41. Khan I, Saeed K, Khan I, Nanoparticles: Properties, Applications and Toxicities, Arab. J. Chem. 2019, 12(7): 908-31
42. Moore JE, Peppas NA, Advanced Drug Delivery Systems: Nanotechnology of Health Design, A Review J. Saudi. Chem. Soc. 2014, 18(2):85-99
43. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V, PLGA-Based Nanoparticles: An Overview of Biomedical Applications J. Control Release. 2012, 161(2):505-522
44. Iyer AK, Khaled G, Fang J, Maeda H, Current trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization, Front Pharmacology. 2018, 9:790
45. Kamaraj I, Kamaraj S, Shanmugam G, Emerging Strategies and Multifunctional Applications of Nanomaterials in Modern Nanomedicine, Medicine in Novel Technology and Devices. 2025, 8:100400